---
figid: PMC8463270__gr2
figtitle: Clinical efficacies, underlying mechanisms and molecular targets of Chinese
  medicines for diabetic nephropathy treatment and management
organisms:
- herbal medicine
- Panax ginseng
- Ginkgo biloba
- Punica granatum
- Panax notoginseng
- Carthamus tinctorius
- Tripterygium wilfordii
- Astragalus membranaceus
- Silybum marianum
- Polygonum cuspidatum
- Schisandra chinensis
- Paeonia lactiflora
- Coptis chinensis
- Dendrobium officinale
- Platycodon grandiflorus
- Panax quinquefolius
- Ligusticum sinense
- Rheum palmatum
- Pyrus pyrifolia
- Moringa oleifera
- Ophiopogon japonicus
- Astragalus mongholicus
- Eucommia ulmoides
- Engelhardia roxburghiana
- Cyclocarya paliurus
- Abelmoschus manihot
- Erigeron breviscapus
- Trichosanthes kirilowii
- Cordyceps cicadae
- Phellodendron chinense
- Mus musculus
- Rattus norvegicus
- Homo sapiens
pmcid: PMC8463270
filename: gr2.jpg
figlink: /pmc/articles/PMC8463270/figure/fig2/
number: F2
caption: Chinese medicines may protect against diabetic nephropathy by antioxidant
  actions via blocking the ET-1 signaling pathway and stimulating NRF2 signaling pathway.
papertitle: Clinical efficacies, underlying mechanisms and molecular targets of Chinese
  medicines for diabetic nephropathy treatment and management.
reftext: Guoyi Tang, et al. Acta Pharm Sin B. 2021 Sep;11(9):2749-2767.
year: '2021'
doi: 10.1016/j.apsb.2020.12.020
journal_title: Acta Pharmaceutica Sinica. B
journal_nlm_ta: Acta Pharm Sin B
publisher_name: Elsevier
keywords: Chinese medicine | Herbal medicine | Diabetic nephropathy | Diabetic kidney
  disease | Signaling pathway | Molecular target | α-SMA, α smooth muscle actin |
  ACEI, angiotensin-converting enzyme inhibitor | ADE, adverse event | AGEs, advanced
  glycation end-products | ATK, protein kinase B | AM, mesangial area | AMPKα, adenosine
  monophosphate-activated protein kinase α | ARB, angiotensin receptor blocker | AREs,
  antioxidant response elements | BAX, BCL-2-associated X protein | BCL-2, B-cell
  lymphoma 2 | BCL-XL, B-cell lymphoma-extra large | BMP-7, bone morphogenetic protein-7
  | BUN, blood urea nitrogen | BW, body weight | C, control group | cAMP, cyclic adenosine
  monophosphate | CCR, creatinine clearance rate | CD2AP, CD2-associated protein |
  CHOP, C/EBP homologous protein | CI, confidence interval | COL-I/IV, collagen I/IV
  | CRP, C-reactive protein | CTGF, connective tissue growth factor | D, duration
  | DAG, diacylglycerol | DG, glomerular diameter | DKD, diabetic kidney disease |
  DM, diabetes mellitus | DN, diabetic nephropathy | eGFR, estimated GFR | eIF2α,
  eukaryotic initiation factor 2α | EMT, epithelial-to-mesenchymal transition | EP,
  E-prostanoid receptor | ER, endoplasmic reticulum | ESRD, end-stage renal disease
  | ET-1, endothelin-1 | ETAR, endothelium A receptor | FBG, fasting blood glucose
  | FN, fibronectin | Gαq, Gq protein alpha subunit | GCK, glucokinase | GCLC, glutamate-cysteine
  ligase catalytic subunit | GFR, glomerular filtration rate | GLUT4, glucose transporter
  type 4 | GPX, glutathione peroxidase | GRB 10, growth factor receptor-bound protein
  10 | GRP78, glucose-regulated protein 78 | GSK-3, glycogen synthase kinase 3 | HbA1c,
  glycosylated hemoglobin | HDL-C, high density lipoprotein-cholesterol | HO-1, heme
  oxygenase-1 | ICAM-1, intercellular adhesion molecule-1 | IGF-1, insulin-like growth
  factor 1 | IGF-1R, insulin-like growth factor 1 receptor | IκB-α, inhibitory protein
  α | IKK-β, IκB kinase β | IL-1β/6, interleukin 1β/6 | IR, insulin receptor | IRE-1α,
  inositol-requiring enzyme-1α | IRS, insulin receptor substrate | JAK, Janus kinase
  | JNK, c-Jun N-terminal kinase | LC3, microtubule-associated protein light chain
  3 | LDL, low-density lipoprotein | LDL-C, low density lipoprotein-cholesterol |
  LOX1, lectin-like oxidized LDL receptor 1 | MAPK, mitogen-activated protein kinase
  | MCP-1, monocyte chemotactic protein-1 | MD, mean difference | MDA, malondialdehyde
  | MMP-2, matrix metallopeptidase 2 | mTOR, mammalian target of rapamycin | MYD88,
  myeloid differentiation primary response 88 | N/A, not applicable | N/O, not observed
  | NOX-4, nicotinamide adenine dinucleotide phosphate-oxidase-4 | NQO1, NAD(P)H:quinone
  oxidoreductase 1 | N/R, not reported | NRF2, nuclear factor erythroid 2-related
  factor 2 | NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells
  | OCP, oxidative carbonyl protein | ORP150, 150-kDa oxygen-regulated protein | p62,
  sequestosome 1 protein | P70S6K, 70-kDa ribosomal protein S6 kinase | PAI-1, plasminogen
  activator inhibitor-1 | PARP, poly(ADP-Ribose) polymerase | PBG, postprandial blood
  glucose | PERK, protein kinase RNA-like eukaryotic initiation factor 2A kinase |
  PGC-1α, peroxisome proliferator-activated receptor gamma coactivator 1α | PGE2,
  prostaglandin E2 | PI3K, phosphatidylinositol 3 kinases | PINK1, PTEN-induced putative
  kinase 1 | p-IRS1, phospho-IRS1 | PKC, protein kinase C | PTEN, phosphatase and
  tensin homolog | RAGE, receptors of AGE | RASI, renin-angiotensin system inhibitor
  | RCT, randomized clinical trial | ROS, reactive oxygen species | SCr, serum creatinine
  | SD, standard deviation | SD-rat, Sprague–Dawley rat | SIRT1, sirtuin 1 | SMAD,
  small mothers against decapentaplegic | SMD, standard mean difference | SMURF-2,
  SMAD ubiquitination regulatory factor 2 | SOCS, suppressor of cytokine signaling
  proteins | SOD, superoxide dismutase | STAT, signal transducers and activators of
  transcription | STZ, streptozotocin | T, treatment group | TBARS, thiobarbituric
  acid-reactive substance | TC, total cholesterol | TCM, traditional Chinese medicine
  | TFEB, transcription factor EB | TG, triglyceride | TGBM, thickness of glomerular
  basement membrane | TGF-β, tumor growth factor β | TGFβR-I/II, TGF-β receptor I/II
  | TII, tubulointerstitial injury index | TLR-2/4, toll-like receptor 2/4 | TNF-α,
  tumor necrosis factor α | TRAF5, tumor-necrosis factor receptor-associated factor
  5 | UACR, urinary albumin to creatinine ratio | UAER, urinary albumin excretion
  rate | UMA, urinary microalbumin | UP, urinary protein | VCAM-1, vascular cell adhesion
  molecule-1 | VEGF, vascular endothelial growth factor | WMD, weight mean difference
  | XBP-1, spliced X box-binding protein 1
automl_pathway: 0.9295034
figid_alias: PMC8463270__F2
figtype: Figure
organisms_ner:
- Mus musculus
redirect_from: /figures/PMC8463270__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8463270__gr2.html
  '@type': Dataset
  description: Chinese medicines may protect against diabetic nephropathy by antioxidant
    actions via blocking the ET-1 signaling pathway and stimulating NRF2 signaling
    pathway.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Nfe2l2
  - Alpha-re
  - Nqo1
  - Gclc
  - Hmox1
  - Vegfa
  - Prdx6
  - Gpx1
  - Gpx3
  - Edn1
  - Ednra
---
